Last A$0.29 AUD
Change Today -0.02 / -6.45%
Volume 142.5K
As of 1:59 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

regeneus ltd (RGS) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/26/13 - A$0.66
52 Week Low
10/28/13 - A$0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REGENEUS LTD (RGS)

Related News

No related news articles were found.

regeneus ltd (RGS) Related Businessweek News

No Related Businessweek News Found

regeneus ltd (RGS) Details

Regeneus Ltd, a regenerative medicine company, is engaged in the creation and manufacture of cell therapies for humans and animals in Australia. Its cell technologies enable the application of regenerative capacities of adipose derived cells, including mesenchymal stem cells for the treatment of musculoskeletal and other inflammatory conditions. The company provides HiQCell, an autologous cell therapy for the treatment of osteoarthritis and tendinopathy in humans. It also offers animal health products comprising CryoShot, an allogeneic cell-based product for treatment therapy for osteoarthritis, and tendon and ligament injuries, as well as as an adjunct to muscular skeletal surgeries in the canine and equine markets. In addition, the company is developing a cell secretions cream for inflammatory skins conditions, such as acne; and CryoShot for human musculoskeletal conditions. Regeneus Ltd was founded in 2007 and is headquartered in Pymble, Australia.

Founded in 2007

regeneus ltd (RGS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: A$275.0K
Executive Chairman, Member of Remuneration & ...
Total Annual Compensation: A$277.7K
Compensation as of Fiscal Year 2013.

regeneus ltd (RGS) Key Developments

Regeneus Ltd Enters into Agreement for US Marketing Trial for Kvax

Regeneus Ltd. announced that it has entered into an agreement with a US vet health care services group to conduct a marketing trial in the United States of the company's novel autologous canine therapeutic cancer vaccine, Kvax. The trial will provide an efficacy data in a single defined tumour type and increase awareness of the new cancer treatment with vets and dog owners in the United States.

Regeneus Ltd. Announces Change of Registered Address

Regeneus Ltd. announced that the registered address for the company has changed to 25 Bridge Street, Pymble, NSW 2073. The telephone and fax numbers and postal address remain unchanged.

Regeneus Ltd Reports Earnings Results for the Half Year Ended December 31, 2013

Regeneus Ltd. reported earnings results for the half year ended December 31, 2013. For the period, the company reported sales revenue of AUD 782,600 against AUD 870,000 a year ago. Total revenue was AUD 868,700 against AUD 933,000 a year ago. EBITDA was AUD 6,191,300 against AUD 3,415,000 a year ago. EBIT was AUD 6,259,200 against AUD 3,502,000 a year ago. Pre-tax loss and loss after tax was AUD 6,364,800 against AUD 3,603,000 a year ago. Negative return on equity was 72.5% against return on equity of 249.7% a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGS:AU A$0.29 AUD -0.02

RGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGS.
View Industry Companies

Industry Analysis


Industry Average

Valuation RGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.9x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENEUS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at